Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models

Martin Tolstrup1†, Claus Johansen2†, Lars Toft1†, Finn S Pedersen3, Anne Funding2, Shervin Bahrami4, Lars Iversen2, Lars Østergaard1 and Mogens Duch3

Abstract

Background: Short dimeric or multimeric peptides derived from a highly conserved stretch of amino acids from gammaretroviral envelope proteins has been found to have immunosuppressive properties in vitro. Here we test the hypothesis that such immunosuppressive peptides may serve as immunomodulatory reagents for treatment of inflammatory disorders.

Results: The anti-inflammatory effect of a synthetic retrovirus-derived immunosuppressive peptide of 17 amino acids was tested in two murine skin inflammation models, a TPA-induced acute toxic contact eczema model and an oxazolone-induced allergic contact dermatitis. Overall, mice (n = 24) treated with a topically applied cream containing the dimeric immunosuppressive peptide exhibited a reduction of 28.8% in ear thickness (range 20.1-42.5), whereas the application of a scrambled peptide dimer or a monomer of the immunosuppressive peptide remained without effect (p = 0.028). Furthermore, ear biopsies from mice treated with the dimeric immunosuppressive peptide showed a significant reduction in mRNA of the pro-inflammatory cytokines TNF-α, IL-17C, and IL-6 as well as the chemokine CXCL2 compared to mice treated with control peptides.

Conclusion: Using two murine skin inflammation models, we show that an immunosuppressive retroviral peptide is capable of reducing inflammatory disorders. The results indicate that virus-derived immunosuppressive peptides capable of down-regulating several proinflammatory cytokines may represent a novel class of drugs for the treatment of excess inflammation.

Background

Several inflammatory diseases are characterized by an unbalanced inflammation and an increased expression of inflammatory cytokines such as TNF-α, IL-6, IL-17A, IL-17C, IL-20, IL-22, IL-23, IFN-γ and CXCL2. Especially TNF-α, IL-17A and IL-12/IL-23 are believed to play a key role in the pathogenesis of psoriasis, which is confirmed by the successful use of antibodies directed against these cytokines in the treatment of psoriasis [1-3]. A subset of these cytokines such as TNF-α, IL-17C, IL-6 and CXCL2 have also been implicated in sepsis [4-8].

It has been known for many years that retroviruses are capable of inhibiting proliferation of immune cells upon stimulation [9-11]. These effects have been localized to the viral fusion protein. Expression of such fusion proteins is sufficient to enable allogenic cells to grow into a tumor in immune competent mice [12]. Immunosuppressive (ISU) fusion proteins have been found in a variety of different viruses with type I fusion mechanism such as retroviruses like MPMV and HIV and in filoviruses such as Ebola and Marburg [13-17]. This ISU-activity was in all these cases located to a very well-defined structure in the transmembrane protein (Figure 1) the ISU effects range from significant inhibition of lymphocyte proliferation [14,15] cytokine skewing (up regulating IL-10; down regulating TNF-α, IL-12, IFN-γ) [18], inhibition of monocytic burst [19], polyclonal B cell activation and cytotoxic T cell activity [20]. Peptides spanning the ISU domain are as active as the whole protein in these assays but only when presented in a dimeric form or coupled to a carrier protein (i.e. >monomeric). Such multimeric peptides are capable of reducing or abolishing...
immune responses like cytokine secretion or proliferation of activated T-cells.

The ISU-domain has been investigated extensively using a 17-meric peptide (CKS-17) derived from murine leukemia virus (MLV) which shows significant immunosuppressive activity in vitro as described above [4,5,21-23].

The ability of CKS-17 to repress T-cell mediated immune responses makes this peptide an interesting drug candidate for the treatment of inflammatory diseases. The aim of this study was to verify the in vivo effects of a retrovirally derived CKS-17 peptide on the immune system. We used two known mouse models for skin inflammation: Acute allergic contact dermatitis model and TPA toxic eczema model [24,25].

In both models, the application of the peptide reduced the inflammation induced by the irritants, thereby confirming the viability of utilization of this virus-derived peptide for treatment of inflammatory diseases.

Results
In order to retain the ISU-peptide on the ears of the mice for longer periods the dissolved peptide was mixed with Natusan®, First Touch Protection cream at a 1:1 ratio to create a homogenous solution. All peptides were freshly dissolved at the start of treatments and stored for 4°C during the animal experiments.

Acute toxic contact eczema model
Two variants of the TPA-induced acute toxic contact eczema model were used to evaluate the anti-inflammatory potential of topical applied CKS-17 peptide. Initially, mice were pretreated for 3 days with peptide-containing cream followed by induction of ear inflammation by TPA. Figure 2A depicts the time-course. Evidently, mice treated with CKS-17 peptide have significantly reduced swelling of the ears upon inflammation induction. The direct comparison with a scrambled peptide in Figure 2B (day 1) points to a specific effect of CKS-17 dimer, which is significantly more potent than the scrambled peptide control to reduce ear inflammation (p < 0.001).

In the same model an experiment was performed in which inflammation was induced five days prior to treatment with peptide cream (Figure 3A). In this setup a monomer peptide vs a dimer was tested since the ISU-activity of the peptides are consistently correlated with di- or multimeric forms of the peptides [14,19,26]. This was confirmed in a direct comparison experiment, where CKS-17 dimer-containing cream significantly reduced ear inflammation in contrast to the monomeric peptide. Figure 3B clearly shows a significant reduction of inflammation two days after CKS-17 dimer treatment in contrast to the monomeric peptide (p = 0.003, Student’s t-test). Monomeric peptide was not different from the pure cream vehicle. Furthermore, in the same experiment we performed a direct comparison to a potent...
anti-inflammatory topical glucocorticoid based cream (Clobetasol propionate 0.05%). Clobetasol propionate treatment was very potent in this model and reduced inflammation close to the basal level with minimal inter-animal variation.

Oxazolone-induced murine allergic contact dermatitis
This model is representative of allergic contact dermatitis induced inflammation by sensitizing the mice 7 days prior to challenge. Three days before induction of inflammation the mice were treated with peptide-containing cream. Evidently, as in the TPA-induced eczema model treatment with CKS-17 containing cream lowered swelling of the ears (Figure 4A) following inflammation induction by oxazolone (day 0). However, the effect was less pronounced at day two post oxazolone challenge (p = 0.068 CKS-17 vs. scrambled, Student’s t-test) as shown in the box-plot in Figure 4B. In general, this contact dermatitis mouse model induces much less inflammation of the ears in comparison to the TPA mouse model. The results of a total of four independent experiments (3 eczema studies and 1 contact dermatitis) each with 6 mice pr treatment group are compiled in Figure 5. The figure depicts the relative reduction in ear thickness of the treatment groups (scrambled/monomer, CKS-17 or Clobetasol propionate) compared with TPA or Oxazolone alone. Across the experiments the reduction in the CKS-17 treatment group ranged from 20-43% with no effect of scrambled/monomer. Clobetasol propionate reduced the swelling of the ears by 80% in the single study where it was applied. The consistent reduction of treatment with CKS-17-containing cream independent of the model and

---

**Figure 2** Ear thickness in an acute toxic contact eczema model (C57BL/6 mice). A) Acute toxic contact eczema model in C57BL/6 mice (n = 6 pr group) pretreated with peptide cream prior to application of TPA. CKS-17 dimér and scrambled CKS-17 dimér used at a concentration of 100 uM. Ear thickness measured each day from onset of TPA treatment. The graph depicts mean with SEM. B) Box-plot with whiskers (5–95 percentile) of ear thickness measurement at day 1 after TPA application. Treatment group comparison performed by students t-test.
The impact of CKS-17 treatment on cytokines implicated in inflammatory diseases

RNA from ear biopsies of the mice treated with TPA (mice depicted in Figure 2) was harvested and subjected to mRNA relative quantification of IL-1α, IL-6, IL-10, IL-17C, TNF-α and CXCL2. All expression levels were adjusted for input mRNA by GAPDH gene expression and the results normalized to levels for vehicle only treated mice. There was a clear and significant reduction of mRNA levels of IL-17C, TNF-α, IL-6 and CXCL2 in mice treated with CKS-17 containing cream (Figure 6, left column). When correlating the relative mRNA expression of these cytokines/chemokines to the ear thickness of individual animals, a statistically significant correlation was observed (Figure 6, right column). In turn, expression levels of neither IL-1α nor IL-10 were affected by treatment with CKS-17-containing cream compared to cream with scrambled peptide. Notably, plotting the expression levels of IL-1α and IL-10 against the ear thickness revealed no linear correlations where observed (Figure 6, right column). The results are summarized in Table 1.

Interestingly, treating mouse ears with cream containing CKS-17 peptide results in a potent blockage of TNF-α mRNA expression (mean index (range) 0.3(0.17-0.52)) to levels below the background in untreated animals in the vehicle control group (mean index (range) 1(0.49-1.51)).

Discussion

In this report we have tested the hypothesis that a retrovirus-derived immunosuppressive peptide may reduce inflammation. We found that a topically delivered retroviral derived peptide (CKS-17) reduced ear inflammation in two different mouse models. Neither a dimeric
version of a scrambled ISU-peptide nor a monomer of the ISU-peptide had any effect, similar to what was previously reported in cell-culture-based assays [9,10,14,15,18-20,26]. The lowering of inflammation in the mouse models can be coupled to significantly reduced expression of key inflammatory cytokines like IL-6, TNF-α and IL-17C.

These results complement those of Cianciolo et al. who recently reported that the CKS-17 ISU-peptide or shorter versions thereof had an immunosuppressive effect in mouse models of inflammatory peritonitis and disseminated intravascular coagulation [27]. Parallel work on hydrophobic regions of HIV-1 gp41, both the fusion peptide and the ISU domain, has suggested control of T cell activation [17,28]. A different applicability of modifying the ISU-peptide from HIV-1 was reported by Morozov and colleagues who were able to enhance the vaccine induced IgG titer towards recombinant gp41 [29].

Previously, TPA-induced skin inflammation in mice has been shown to involve potent upregulation of TNF-α [30,31]. Here we report that TNF-α expression levels were the most severely affected cytokine level by peptide treatment. Despite a four-fold increase in mRNA by TPA treatment the application of CKS-17 containing cream reduced TNF-α expression to below baseline levels (average of 70% reduction compared to baseline). In addition, levels of another important regulator in autoimmune diseases, IL-17C was significantly reduced upon treatment of inflamed ears with cream containing retroviral peptide. Recently, anti-IL-17A receptor antibodies have proven successful in early clinical trials [2,30].
Interestingly, we find that the level of IL-1\(\alpha\) expression is not regulated by CKS-17 peptide application. Considering the effect of IL-1\(\alpha\) in the contact acute eczema model this was somewhat surprising although in agreement with earlier studies of the intrinsic effects of retrovirus-derived envelope peptides highlighting that CKS-17 does not block production of IL-1\(\alpha\) but reduce the immunobiological effect [20]. The varied effect on several key cytokines suggests that the local application of peptide containing cream pursued in this study could be of greater relevance than systemic use of monoclonal antibodies mainly because of the plethora of targets and the fact that for example anti-TNF-\(\alpha\) blockers carry increased infection risks [32].

In the model of Oxazolone induced inflammation a similar trend was observed in that ear inflammation was reduced in peptide treated mice. The degree of inflammation induced in this model is of a smaller magnitude. In turn, the relative reduction by peptide treatment was comparable to what was obtained in the TPA-induced model suggesting that the peptide did indeed impact this model as well, although the inhibitory effect failed to reach statistical significance. In this model we have previously shown mitogen-activated protein kinase AP (MAPKAP) kinase 2 regulated TNF-\(\alpha\) as important for ear inflammation [24].

**Conclusion**

We have shown that the immunosuppressive retroviral peptide CKS-17 is capable of reducing proinflammatory cytokines as well as the level of inflammation as measured by ear thickness in two mouse models of inflammatory skin disease. Together with the work of Cianciolo et al. [27] our results indicate that virus-derived immunosuppressive peptides capable of downregulating several proinflammatory cytokines such as TNF-\(\alpha\), IL-6, and IL-17C may represent a novel class of drugs for the treatment of excess inflammation.

**Methods**

**Peptides**

CKS-17 peptide (LQNRRGLDLLFLKEGGL) or scrambled CKS-17 (LGGEKLFLLDLGRRNQLC) both linked into dimers via the C-terminal cysteine were purchased as lyophilized powder from Anaspec (California, USA). CKS-17 monomer was purchased without the C-terminal disulphide linkage. All peptides were dissolved in sterile water.

**Mice**

BALB/cj and C57BL/6 mice were purchased from Tacolic Europe (Ry, Denmark). All mice used in this study were female and 6–8 weeks of age when experiments were initiated. The animals were kept in animal facilities that maintained a temperature of 19–25°C, and a 12-hour day/night cycle. They were given access to food and water ad libitum. All experiments were approved by the Committee for Animal Experiments in Denmark.

**Acute toxic contact eczema model**

Two different dosings were pursued in this model. Firstly, C57BL/6 mice were treated once daily from day −3 until day 3 on the ears with cream (commercially available baby lotion; Natusan®, First Touch Protection cream) + 50% H2O) alone, cream + scrambled peptide or cream + CKS-17 peptide. Before the first application of cream at day −3 the ear thickness was measured. At day 0 and day 2 (3 hours before treatment with cream) the mice were treated with phorbol 12-myristate 13-acetate (TPA)(Sigma-Aldrich, St Louis, MO, cat no. P8139) on the ears (2 \(\mu\)g/ear). TPA was dissolved in acetone. Before the first challenge of TPA the ear thickness was measured (day 0) and again post-challenge at the times indicated, using a Mitutoyo digimatic indicator. At day 5 and 7 the mice were treated one time with either cream alone,
Figure 6 (See legend on next page.)
cream + CKS-17 monomér, cream + CKS-dimér or Clobetasolpropionat 0.05% cream formulation applied neat (GSK, UK). The mice were anaesthetised during the ear measurement.

**Oxazolone-induced murine allergic contact dermatitis**

4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone) was purchased from Sigma-Aldrich (cat no. E0753). Oxazolone was dissolved in acetone. At day − week mice were sensitized with 1.5% oxazolone by application to the clipped abdomen (100 μl). Once daily from day −3 until day 1 the ears of the mice were treated with cream (commercial available baby lotion; Natusan®, First Touch Protection cream + natural sunblock). At termination of one study of acute toxic contact eczema at which time they were transferred to RNA purification at which time they were transferred to RNA lysis buffer added β-mercaptoethanol (SV Total RNA Isolation System; Promega, Madison, WI) and homogenized. RNA purification was completed according to the manufacturer’s instructions (SV Total RNA Isolation System; Promega). RNA was stored until further use at −80°C.

RNA isolation

At termination of one study of acute toxic contact eczema punch biopsies (4 mm) from mice ears were transferred to 1 ml of −80°C cold RNAlater-ICE (Ambion inc., Austin, TX). Samples were kept at −80°C until 24 hours before RNA purification at which time they were transferred to −20°C. On RNA purification, biopsies were removed from RNAlater-ICE and transferred to 175 μl of SV RNA lysis buffer added β-mercaptoethanol (SV Total RNA Isolation System; Promega, Madison, WI) and homogenized. RNA purification was completed according to the manufacturer’s instructions (SV Total RNA Isolation System; Promega). RNA was stored until further use at −80°C.

**Quantitative polymerase chain reaction (qPCR)**

For reverse transcription, Taqman Reverse Transcription reagents (Applied Biosystems, Foster City, CA, U.S.A.) were used. For qPCR we used Platinum® qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, U.S.A.) with primers and probes were Taqman 20x Assays-On-Demand (FAM-labeled MGB-probes) gene expression assay mix (Applied Biosystems). Each sample was loaded as triplets and analyzed on a Rotorgene-3000 real-time PCR machine (Corbett Research, Cambridge, U.K.). Relative gene expression levels were determined by using the relative standard curve method as outlined in User Bulletin 2 (ABI PRISM 7700 sequencing detection system, Applied Biosystems). Briefly, a standard curve for each gene was made of fourfold serial dilutions of total RNA from a punch biopsy from the ears of mice. The curve was then used to calculate relative amounts of target mRNA in the samples. As housekeeping GAPDH was used. Assay ID for the primers and probes used in this study were as follows: IL-17c (Mm00439619_m1); TNF-α (Mm00443258_m1); IL-1α (Mm00439620_m1); IL-6 (Mm00443260_m1); IL-10 (Mm00439616_m1); CXCL2 (Mm0043450_m1); GAPDH (Mm9999991_g1).

**Statistics**

Comparisons of ear thickness and relative mRNA levels between treatment groups were performed using a student’s t-test. Correlations between ear thickness and mRNA levels were determined using spearman correlations. Lastly, the percentage effect on reduction in ear thickness between scrambled and CKS-17 treated groups across four independent mouse experiments were compared using a Mann–Whitney test. All p-values reported are two-tailed and we set the significance level at 5%.

**Table 1 Cytokine mRNA expression index from ear biopsies**

|          | Vehicle | TPA | TPA w. scrambled | TPA w. CKS-17 | p-value |
|----------|---------|-----|------------------|--------------|---------|
| IL-1α    | 1(0.77–1.22) | 3.64(2.76–5.55) | 2.82(1.97–4.31) | 2.1(1.21–3.67) | 0.143   |
| IL-6     | 1(0.81–1.19) | 39.3(13.4–73.5) | 217(12.9–976) | 4.23(1.82–6.39) | 0.068   |
| IL-10    | 1(0.95–1.04) | 563(3.49–9.16) | 8.75(4.01–18.47) | 3.61(1.00–5.49) | 0.071   |
| IL-17c   | 1(0.54–1.46) | 4.17(1.04–7.54) | 3.34(0.81–8.12) | 0.85(0.24–1.54) | 0.744   |
| TNF-α    | 1(0.49–1.51) | 3.93(0.36–10.1) | 7.27(0.48–23.3) | 0.3(0.17–0.52) | 0.040   |
| CXCL2    | 1(0.41–1.59) | 1162(402–2846) | 7339(123–29363) | 86(6.7–358) | 0.432   |
Competing interests
The authors declare that they have no competing interests.

Authors’ contribution
MT designed experiments, performed experiments, performed data analysis
and wrote the manuscript. CJ designed experiments, performed experiments
and wrote the manuscript. LT performed experiments. FSP wrote the
manuscript. AF designed experiments, SB designed experiments, LI
designed experiments, LO designed experiments, MD designed experiments,
performed data analysis and wrote the manuscript. All authors read and
approved the final manuscript.

Acknowledgements
This study was supported by a grant from the Aarhus University Hospital
Research Fund and a proof-of-concept grant from Aarhus University.

References
1. Leonard CL, Kimball AB: Efficacy and safety of ustekinumab, a human
interleukin-12/23 monoclonal antibody, in patients with psoriasis:
76-week results from a randomised, double-blind, placebo-controlled
trial (PHENIX 1). Lancet 2008, 371(9615):1674–1684.
2. Leonard C, Matheson R: Anti-interleukin-17 monoclonal antibody
etuximab in chronic plaque psoriasis. N Engl J Med 2012, 366(6):1190–1199.
3. Valesini G, Iannucelli C: Biological and clinical effects of anti-TNFαlophath
 Autoimmun Rev 2007, 7:35–41.
4. Craciun FL, Schuller ER, Remig D: Early enhanced local neutrophil
 recruitment in peritonitis-induced sepsis improves bacterial clearance
and survival. J Immunol 2010, 185(1):650–693.
5. Villar J, Pérez-Méndez L: A CXCL2 polymorphism is associated with
better outcomes in patients with severe sepsis. Crit Care Med 2007,
35(10):2292–2297.
6. Kim SD, Kim YK: The agonists of formyl peptide receptors prevent
 development of severe sepsis after microbial infection. J Immunol 2010,
185(7):4302–4310.
7. Hillembrand A, Knippich I: Sepsis induced changes of adipokines and
cytokines - septic patients compared to morbibly obese patients.
BMC Surg 2010, 9:10–26.
8. Hamishekar H, Beigmohammadi MT: Identification of enhanced cytokine
generation following sepsis. Dream of magic bullet for mortality
prediction and therapeutic evaluation. Davan 2010, 18(3):155–162.
9. Cianciolo Gi, Lofstrom ME: Marine malignant cells synthesize a 19,000-
dalton protein that is physicochemically and antigenically related to
the immunosuppressive retroviral protein, P15E. J Exp Med 1983,
158(3):885–900.
10. Høibebrand LC, Olsen RG: Inhibition of human lymphocyte mitogen and
antigen response by a 1,000-dalton protein from feline leukemia virus.
Cancer Res 1979, 39:443–447.
11. Cianciolo Gi, Matthews TJ: Macrophage accumulation in mice is inhibited
by low molecular weight products from murine leukemia viruses.
J Immunol 1980, 124(5):2900–2905.
12. Mangeney M, Heidmann T: Tumor cells expressing a retroviral envelope
escape immune rejection in vivo. Proc Natl Acad Sci USA 1998,
95(25):14190–14195.
13. Mangeney M, Renard M: Placental syncytiotrophoblasts: genetic disjunction between
the fusogenic and immunosuppressive activity of retroviral envelope
proteins. Proc Natl Acad Sci USA 2007, 104(51):20534–20539.
14. Cianciolo Gi, Copeland TD: Inhibition of lymphocyte proliferation by a
synthetic peptide homologous to retroviral envelope proteins.
Science 1985, 230(4742):453–455.
15. Cianciolo Gi, Bogerd H, Snyderman R: Human retrovirus-related synthetic
peptides inhibit T lymphocyte proliferation. Immunol Lett 1988, 19(1):7–13.
16. Yaddanapudi K, Palacios G: Implication of a retrovirus-like glycoprotein
peptide in the immunopathogenesis of Ebola and Marburg viruses.
FASEB J 2006, 20(14):2519–2520.
17. Bloch L, Quintana FJ: T-cell inactivation and immunosuppressive
activity induced by HIV gp41 via novel interacting motif. FASEB J 2007,
21(2):393–401.
18. Haraguchi S, Good RA: Differential modulation of Th1 and Th2 related
cytokine mRNA expression by a synthetic peptide homologous to a
conserved domain within retroviral envelope protein. Proc Natl Acad Sci
USA 1995, 92(26):13611–13615.
19. Harrell RA, Cianciolo Gi: Suppression of the respiratory burst of human
monocytes by a synthetic peptide homologous to envelope proteins of
human and animal retroviruses. J Immunol 1986, 136:3517–3520.
20. Kleinerman ES, Lachman LB: A synthetic peptide homologous to the
envelope proteins of retroviruses inhibits monocyte mediated killing
by inactivating interleukin 1. J Immunol 1987, 139:2329–2337.
21. Finkelman FD, Hogan SP: Importance of cytokines in murine allergic
airway disease and human asthma. J Immunol 2010, 184(4):1663–1674.
22. Corren J: Cytokine inhibition in severe asthma: current knowledge and
future directions. Curr Opin Pulm Med 2011, 17(1):29–33.
23. Davelaëlle L, Duvallé E: Anti-cytokine vaccination in autoimmune
diseases. Swiss Med Wkly 2010, 140:w13108.
24. Funding AT, Johansen C: Reduced oxaolzone-induced skin inflammation
in MAPKAP kinase 2 knockout mice. J Invest Dermatol 2009, 129:891–898.
25. Lilholt LL, Johansen C: Role of p38 mitogen-activated protein kinase
isoforms in murine skin inflammation induced by 12-O-
tetradecanoylphorbol 13-acecitate. Acta Derm Venereal 2011, 91:271–278.
26. Takahashi A, Day NK: A retroviral-derived immunosuppressive peptide
activates mitogen-activated protein kinases. J Immunol 2001,
166:6771–6775.
27. Cianciolo Gi, Pizzo SV: Anti-inflammatory and vasoprotective activity of
a retroviral-derived peptide, homologous to human endogenous
retroviruses: endothelial cell effects. PloS One 2012, 7(12):e52693.
28. Ashkenazi A, Faingold O: HIV-1 fusion protein exerts complex
immunosuppressive effects. Trends Biochem Sci 2013, 38(7):345–349.
29. Morozov VA, Morozov AV: Single mutations in the transmembrane
envelope protein abrogate the immunosuppressive properties of HIV-1.
Retrovirology 2012, 9:67.
30. Kalyon Kumar G, Dhamotharan R: Embelin reduces cutaneous TNFα-a
level and ameliorates skin edema in acute and chronic model of skin
inflammation in mice. Eur J Pharmacol 2011, 662:43–49.
31. Pagu KA, Reid C: Anti-IL-17 receptor antibody AMG 827 leads to rapid
clinical response in subjects with moderate to severe psoriasis: results
from a phase I randomized, placebo-controlled trial. J Invest Dermatol
2012, 132:2466–2469.
32. Galloway JB, Hyrich KL: Anti-TNF therapy is associated with an increased
risk of serious infections in patients with rheumatoid arthritis especially
in the first 6 months of treatment: updated results from the British
Society for Rheumatology Biologics Register with special emphasis on
risks in the elderly. Rheumatology 2011, 50:124–131.

doi:10.1186/1471-2172-14-51
Cite this article as: Tolstrup et al.: Anti-inflammatory effect of a
retrovirus-derived immunosuppressive peptide in mouse models. BMC
Immunology 2013 14:51.